Daily Cardiology Research Analysis
Analyzed 144 papers and selected 3 impactful papers.
Summary
Top advances span basic-to-clinical cardiology: a mechanistic study identifies the olfactory receptor Olfr2/OR6A2 as a driver of monocyte recruitment and inflammation in abdominal aortic aneurysm, suggesting a new therapeutic target. A translational study reveals methylmalonic acid as a biomarker and mechanistic amplifier of myocardial ischemia-reperfusion injury. A large registry-derived model accurately predicts 1-year heart failure hospitalization or death after TAVR, enabling targeted follow-up.
Research Themes
- Inflammation and immune mechanisms in vascular disease
- Translational biomarkers and mitochondrial metabolism in myocardial injury
- Risk stratification and prognostic modeling after structural heart interventions
Selected Articles
1. Olfr2 Promotes Recruitment of Monocytes via CX3CR1 in Abdominal Aortic Aneurysm.
This mechanistic study shows that the olfactory receptor Olfr2 (human ortholog OR6A2) is upregulated in AAA, promotes CX3CR1-mediated monocyte recruitment and macrophage-driven inflammation, and that genetic deletion or pharmacologic inhibition of Olfr2 protects against AAA in vivo. Conversely, receptor activation exacerbates disease, nominating Olfr2/OR6A2 as a therapeutic target.
Impact: Identifying a GPCR that orchestrates monocyte recruitment in AAA provides a druggable target with immediate translational potential and reframes innate immune signaling in aneurysm biology.
Clinical Implications: Olfr2/OR6A2 blockade could attenuate aneurysm progression by reducing monocyte influx and macrophage activation; OR6A2 expression might also serve as a biomarker for inflammatory AAA activity.
Key Findings
- OR6A2 (human ortholog of Olfr2) expression is increased in human AAA tissue and in circulating monocytes from patients with large AAAs.
- Up to ~30% of vascular macrophages in human and murine AAA express OR6A2/Olfr2, enriched in MHCII-high subsets.
- Genetic deletion or pharmacologic inhibition of Olfr2 protects against AAA development in vivo; receptor activation worsens aneurysm burden.
- Olfr2 promotes monocyte recruitment via CX3CR1 signaling, linking GPCR sensing to leukocyte trafficking in AAA.
Methodological Strengths
- Integrated human tissue profiling (microarray, flow cytometry) with in vivo genetic and pharmacologic perturbations.
- Convergent evidence across human and murine systems implicating the same receptor and cell type.
Limitations
- Preclinical nature without randomized clinical validation or therapeutic trials in humans.
- Ligand specificity and potential off-target effects of pharmacologic modulators are not fully detailed in the abstract.
Future Directions: Define endogenous ligands and signaling dynamics of OR6A2/Olfr2 in human AAA, develop selective antagonists, and test Olfr2-targeted therapies in preclinical large-animal models and early-phase clinical trials.
BACKGROUND: Abdominal aortic aneurysms (AAAs) are characterized by ECM (extracellular matrix) degradation and chronic vascular inflammation, with macrophages playing a key role. The mechanisms regulating macrophage activation in AAA remain incompletely understood. Vascular macrophages express Olfr2 (olfactory receptor 2), a GPCR (G-protein-coupled receptor) implicated in inflammation, but its role in AAA development is unknown. METHODS: We investigated the role of Olfr2 in AAA using PPE (porcine pancreatic elastase) infusion in Olfr2-deficient ( RESULTS: Microarray analysis revealed increased expression of the human Olfr2 orthologue OR6A2 in AAA tissue. Flow cytometry showed OR6A2 upregulation in monocytes from patients with large versus small AAAs. In both human and murine tissues, up to 30% of vascular macrophages expressed OR6A2/Olfr2, which peaked in MHCII CONCLUSIONS: Olfr2 regulates monocyte recruitment and macrophage-driven inflammation during AAA. Its genetic deletion or pharmacological inhibition protects against AAA, whereas receptor activation worsens the disease. Olfr2 represents a critical modulator of vascular inflammation and a potential therapeutic target in AAA.
2. Methylmalonate accumulation contributes to myocardial vulnerability post-reperfusion: a novel therapeutic target and prognostic biomarker.
Across three human cohorts and multiple animal models, circulating methylmalonic acid (MMA) predicted myocardial injury/heart failure after reperfusion and mechanistically amplified I/R damage by disrupting mitochondrial bioenergetics, biogenesis, and renewal via SIRT1 inhibition and downstream transcriptional effects. Targeting MMA metabolism mitigated injury in a porcine model, highlighting MMA as both a biomarker and therapeutic target.
Impact: This work connects a specific mitochondrial metabolite to both prognostication and mechanism of reperfusion injury, and demonstrates therapeutic tractability in a large-animal model.
Clinical Implications: MMA quantification could refine early risk stratification after AMI reperfusion. Pharmacologic approaches that reduce MMA accumulation or preserve SIRT1 signaling may mitigate myocardial injury.
Key Findings
- In three human cohorts, circulating MMA predicted myocardial injury and heart failure risk post-reperfusion and outperformed succinate.
- In mice, MMA and succinate rose early after I/R, but only MMA remained elevated; endogenous/exogenous MMA heightened I/R susceptibility and mitochondrial dyshomeostasis.
- Mechanistically, MMA inhibited SIRT1 deacetylase activity, leading to transcriptional changes (e.g., CREB hyperacetylation) that impair mitochondrial bioenergetics/biogenesis.
- Targeting MMA metabolism reduced myocardial injury in a porcine I/R model, supporting translational potential.
Methodological Strengths
- Multi-cohort human validation integrated with mouse genetics, exogenous metabolite challenge, and large-animal (porcine) testing.
- Mechanistic depth using multiomics, ChIP, and mutagenesis to link metabolite accumulation to transcriptional control and mitochondrial function.
Limitations
- Exact human sample sizes and cohort characteristics are not specified in the abstract, limiting appraisal of population heterogeneity.
- Clinical interventional evidence is preliminary; therapeutic strategies require human trials to assess efficacy and safety.
Future Directions: Prospective clinical studies to validate MMA as a prognostic biomarker post-AMI and early-phase trials of MMA-lowering or SIRT1-preserving therapies to reduce reperfusion injury.
BACKGROUND: Dysfunctional mitochondria are a prominent feature of myocardial ischemic-reperfusion (I/R) injury, but the clinical translation is scarce. Congenital dysbolism methylmalonic acidemia causes fatal mitochondrial lesions and premature death. However, the biological impact of mitochondrial metabolite methylmalonic acid (MMA) in the pathogenesis of I/R and its translational relevance were unknown. METHODS: MMA and relevant metabolites were measured in 3 independent human cohorts and animals. Cardiac Mmut-conditional knockout (endogenous MMA elevation) and exogenous MMA administration were conducted in mouse I/R model. The potential mechanism was explored through multiomics, chromatin immunoprecipitation, and site-directed mutagenesis assays. The translational value of targeting MMA metabolism was assessed in a porcine I/R model. RESULTS: Circulating MMA predicts myocardial injury or heart failure risk post-reperfusion, which outmatches its isomer succinate in humans. Both MMA and succinate were elevated in heart tissues of mice at the initial period post-I/R, while later, MMA maintained higher levels, but succinate rapidly decreased to baseline levels. Endogenous and exogenous MMA, not succinate, increased susceptibility to myocardial I/R injury and mitochondrial dyshomeostasis, including impaired mitochondrial bioenergetics, biogenesis, and renovation. Mechanistically, MMA elevation inhibited the deacetylase activity of SIRT1; thus, hyperacetylation of transcription factor CREB CONCLUSIONS: This study revealed an unrecognized harmful effect of MMA on myocardial vulnerability distinct from its isomer succinate. Targeting MMA metabolism represents a promising strategy to optimize risk stratification and mitigate myocardial injury in patients with AMI.
3. Prediction of Heart Failure Hospitalization or Death After TAVR.
Using 78,384 patients from the TVT Registry, the authors developed and internally validated a hierarchical model with strong discrimination (C≈0.75) and excellent calibration to predict 1-year death or HF readmission after TAVR. A 12-variable simplified model retained performance, supporting adoptability for clinical surveillance and trial enrollment.
Impact: A large, well-performing prediction tool addresses a major unmet need in post-TAVR care by enabling proactive, risk-guided management and resource allocation.
Clinical Implications: Clinicians can use the model to identify high-risk patients for intensified monitoring, optimization of guideline-directed therapy, and enrollment in trials of adjunctive HF therapies post-TAVR.
Key Findings
- Among 78,384 post-TAVR patients who survived to discharge, 17.4% experienced the composite of 1-year death or HF readmission.
- The hierarchical cumulative odds model achieved C-statistics of 0.753 (derivation) and 0.747 (validation) with excellent calibration.
- A simplified 12-variable model preserved performance (C≈0.74–0.75), facilitating clinical implementation.
- Predictive performance for isolated HF readmission among 1-year survivors was similar (C=0.753).
Methodological Strengths
- Very large, contemporary national registry with robust internal validation and excellent calibration.
- Development of a simplified model retaining performance enhances usability and adoption.
Limitations
- Internal validation only; lack of external validation may limit generalizability across health systems.
- Registry-based modeling is subject to residual confounding and variable availability constraints.
Future Directions: External validation across diverse healthcare systems and integration into clinical workflows with decision-support tools; evaluate impact on outcomes through implementation studies.
BACKGROUND: Heart failure (HF) remains a significant burden following transcatheter aortic valve replacement, adversely impacting survival and quality of life. Identification of patients who may benefit from closer monitoring or adjunctive medical therapy to reduce the risk of HF is an unmet need. The objective of this study was to develop and internally validate a clinical prediction model to determine the 1-year risk of HF hospitalization or death after transcatheter aortic valve replacement. METHODS: Using the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry, we analyzed patients who underwent successful transcatheter aortic valve replacement for aortic stenosis and survived to discharge between 2016 and 2019. Covariates were selected based on expert opinion and prior literature. A hierarchical cumulative odds regression model was used to predict a composite outcome of (1) all-cause death, (2) ≥2 HF readmissions, or (3) 1 HF readmission at 1 year. RESULTS: Among 78 384 patients (median age, 82 years; 45.6% female), 17.4% experienced the composite outcome, including death (10.9%), ≥2 HF readmissions (1.6%), and 1 HF readmission (4.9%). The model demonstrated good discrimination (C statistic, 0.753 derivation and 0.747 validation) and excellent calibration. Among 1-year survivors, performance in predicting HF readmission as an isolated outcome was similar (C statistic, 0.753). A simplified model, including the top 12 variables from the full model, maintained comparable performance (C statistics, 0.74-0.75). CONCLUSIONS: This prediction model effectively stratifies post-transcatheter aortic valve replacement patients by risk of death or HF readmission, supporting its use to guide clinical surveillance and clinical trial enrollment for adjunctive medical therapies aimed at mitigating this risk.